Literature DB >> 15756001

Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.

Kshama R Mehta1, Kentaro Nakao, Marlene B Zuraek, Daniel T Ruan, Emily K Bergsland, Alan P Venook, Dan H Moore, Taku A Tokuyasu, Ajay N Jain, Robert S Warren, Jonathan P Terdiman, Frederic M Waldman.   

Abstract

PURPOSE: Although liver resection is the primary curative therapy for patients with colorectal hepatic metastases, most patients have a recurrence. Identification of molecular markers that predict patients at highest risk for recurrence may help to target further therapy. EXPERIMENTAL
DESIGN: Array-based comparative genomic hybridization was used to investigate the association of DNA copy number alterations with outcome in patients with colorectal liver metastasis resected with curative intent. DNA from 50 liver metastases was labeled and hybridized onto an array consisting of 2,463 bacterial artificial chromosome clones covering the entire genome. The total fraction of genome altered (FGA) in the metastases and the patient's clinical risk score (CRS) were calculated to identify independent prognostic factors for survival.
RESULTS: An average of 30 +/- 14% of the genome was altered in the liver metastases (14% gained and 16% lost). As expected, a lower CRS was an independent predictor of overall survival (P = 0.03). In addition, a high FGA also was an independent predictor of survival (P = 0.01). The median survival time in patients with a low CRS (score 0-2) and a high (> or =20%) FGA was 38 months compared with 18 months in patients with a low CRS and a low FGA. Supervised analyses, using Prediction Analysis of Microarrays and Significance Analysis of Microarrays, identified a set of clones, predominantly located on chromosomes 7 and 20, which best predicted survival.
CONCLUSIONS: Both FGA and CRS are independent predictors of survival in patients with resected hepatic colorectal cancer metastases. The greater the FGA, the more likely the patient is to survive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756001     DOI: 10.1158/1078-0432.CCR-04-1418

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases.

Authors:  Timothy M Pawlik; Michael A Choti
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

Review 2.  Predictors of long-term survival in patients with colorectal liver metastases: a single center study and review of the literature.

Authors:  Utz Settmacher; Yves Dittmar; Thomas Knösel; Ulrike Schöne; Michael Heise; Karin Jandt; Annelore Katharina Altendorf-Hofmann
Journal:  Int J Colorectal Dis       Date:  2011-05-17       Impact factor: 2.571

3.  PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.

Authors:  George Poulogiannis; Rebecca E McIntyre; Maria Dimitriadi; John R Apps; Catherine H Wilson; Koichi Ichimura; Feijun Luo; Lewis C Cantley; Andrew H Wyllie; David J Adams; Mark J Arends
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

Review 4.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 5.  Surgery for colorectal liver metastases: The evolution of determining prognosis.

Authors:  Gaya Spolverato; Aslam Ejaz; Nilo Azad; Timothy M Pawlik
Journal:  World J Gastrointest Oncol       Date:  2013-12-15

6.  Specific genomic aberrations in primary colorectal cancer are associated with liver metastases.

Authors:  Sjoerd C Bruin; Christiaan Klijn; Gerrit-Jan Liefers; Linde M Braaf; Simon A Joosse; Eric H van Beers; Victor J Verwaal; Hans Morreau; Lodewyk F Wessels; Marie-Louise F van Velthuysen; Rob A E M Tollenaar; Laura J Van't Veer
Journal:  BMC Cancer       Date:  2010-12-02       Impact factor: 4.430

Review 7.  Tumor immunosurveillance in human cancers.

Authors:  Bernhard Mlecnik; Gabriela Bindea; Franck Pagès; Jérôme Galon
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

8.  Tumor genome wide DNA alterations assessed by array CGH in patients with poor and excellent survival following operation for colorectal cancer.

Authors:  Kristina K Lagerstedt; Johan Staaf; Göran Jönsson; Elisabeth Hansson; Christina Lönnroth; Ulf Kressner; Lars Lindström; Svante Nordgren; Ake Borg; Kent Lundholm
Journal:  Cancer Inform       Date:  2007-10-12

9.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays.

Authors:  Yuker Wang; Victoria E H Carlton; George Karlin-Neumann; Ronald Sapolsky; Li Zhang; Martin Moorhead; Zhigang C Wang; Andrea L Richardson; Robert Warren; Axel Walther; Melissa Bondy; Aysegul Sahin; Ralf Krahe; Musaffe Tuna; Patricia A Thompson; Paul T Spellman; Joe W Gray; Gordon B Mills; Malek Faham
Journal:  BMC Med Genomics       Date:  2009-02-19       Impact factor: 3.063

10.  Impact of chromosomal instability on colorectal cancer progression and outcome.

Authors:  Béatrice Orsetti; Janick Selves; Caroline Bascoul-Mollevi; Laurence Lasorsa; Karine Gordien; Frédéric Bibeau; Blandine Massemin; François Paraf; Isabelle Soubeyran; Isabelle Hostein; Valérie Dapremont; Rosine Guimbaud; Christophe Cazaux; Michel Longy; Charles Theillet
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.